Business

CVRx to Present at the William Blair 46th Annual Growth Stock Conference

MINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that the management team will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Tuesday, June 2, 2026. The Company's presentation will begin at 10:40 a.m. (CT). A live webcast of the event can b

articleCvrx, Inc.May 20, 20261/company/cvrx-inc/news/cvrx-to-present-at-the-william-blair-46th-annual-growth-stock-conference
CVRx to Present at the William Blair 46th Annual Growth Stock Conference

About this update from Cvrx, Inc.

[{"type":"image","alt":"CVRx, Inc.","displaySize":"","headline":null,"caption":"CVRx, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":119,"url":"https://media.zenfs.com/en/globenewswire.com/df09df0c7616e5d7c04e1cae1c854256"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jMCkCGQ7b_B17NxKmbJDHg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2Nw--/https://media.zenfs.com/en/globenewswire.com/df09df0c7616e5d7c04e1cae1c854256","width":300,"height":119},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/jMCkCGQ7b_B17NxKmbJDHg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2Nw--/https://media.zenfs.com/en/globenewswire.com/df09df0c7616e5d7c04e1cae1c854256","width":300,"height":119}},"lazy":false},{"type":"text","content":"MINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that the management team will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Tuesday, June 2, 2026. The Company's presentation will begin at 10:40 a.m. (CT).","length":470,"tagName":"p"},{"type":"text","content":"A live webcast of the event can be found at ir.cvrx.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.","length":200,"tagName":"p"},{"type":"text","content":"About CVRx, Inc.","length":16,"tagName":"p"},{"type":"text","content":"CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.","length":577,"tagName":"p"},{"type":"text","content":"Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compli...

More updates from Cvrx, Inc.

CVRx, Inc.William Blaircardiovascular diseasesCVRXimplantable deviceneuromodulation